Board of Directors
Board of Directors BiographiesSteven Nissen, MD, Chairman of the BoardChairman, Department of Cardiovascular Medicine, Cleveland Clinic Dr. Nissen is the -chairman of cardiology at The Cleveland Clinic Foundation. Board-certified in internal medicine and cardiovascular medicine, he is a professor of medicine at The Ohio State University. Dr. Nissen is an elected member of the American College of Cardiology (ACC) Board of Trustees and several other ACC committees, including the Eductional Products committee and the Information Tehnology Committee. He also serves on the editorial boards of nine scientific publications, including the International Journal of Cardiac Imaging, Cardiology Today and Clinical Cardiology. In 1993 and 1998, Dr. Nissen received the Cleveland Clinic Outstanding Teacher Award. He has played an important role in numerous clinical trials, lectures frequently on the use of intravascular ultrasound and has authored several dozen book chapters and more than 100 articles in scientific journals such as Circulation, the Journal of the American College of Cardiology and the American Journal of Cardiology. A graduate of the University of Michigan School of Medicine at Ann Arbor, Dr. Nissen completed his internship and residencies in internal medicine at the University of California-Davis and his cardiology fellowship at the University of Kentucky Medical Center in Lexington, Kentucky. Michael
Barber Michael is a graduate of the Milwaukee School of Engineering where he received a degree in Electrical Engineering. While attending MSOE Michael co-founded the school’s NSBE chapter. He interned at GE Medical Systems and has worked there for his entire professional career. Michael has held various engineering and operations design and leadership positions at GE Healthcare. He started as an electronics design engineer in the Xray Product Development Group, developed the control architecture (Advantx) for the Xray product line as a SW project leader, managed the HW, Firmware and Diagnostics team at CT, and managed the Functional Engineering team in the MR business. Michael returned to Xray as the Manager of the Digital Xray Detector Platform, which replaced the need for film in Xray procedures. He then held engineering and operations leadership roles in Imaging Subsystems and was named VP Technology of the Diagnostics Imaging Business in May 2005. His current position is Chief Technology Officer for GE Healthcare. GEHC has over 5000 engineers and scientists working in diverse fields such as MR and CT scanners, patient monitoring, anesthesia, life sciences and imaging contrast agents. Michael was named a company officer in July 2006. Chris Coburn Mr. Coburn has been Executive Director of CCFI since its establishment in 2000 and is responsible for all activities and outcomes of the department. He is a recognized authority of technology commercialization and has consulted and spoken on the subject throughout North America and in 18 countries. He leads a team of a dozen industry veterans. Mr. Coburn serves on the board of directors of CleveX, Merlot Therapeutics, PeriTec, PrognostiX, and BioEnterprise. He is a trustee of Hathaway Brown School, Northeast Ohio Council of Higher Education, and Town Hall of Cleveland. He is a former director of the U.S. Enrichment Corporation ( NYSE:USU) and author of numerous articles and book chapters on technology commercialization. He was editor and co-author of Partnerships, a key reference book on technology commercialization. His Master’s Degree is from George Washington University. Paul
DiCorleto, PhD Dr. Paul E. DiCorleto is Chairman of the Department of Molecular Medicine, Case School of Medicine and Chairman of the Lerner Research Institute of the Cleveland Clinic, home to over 130 principal investigators and 1000 employees performing biomedical research. Dr. DiCorleto received his undergraduate training in chemistry at Rensselaer Polytechnic Institute and his doctorate in biochemistry from Cornell University. Dr. DiCorleto’s research focuses on the molecular and cellular basis of atherosclerosis. He has been with the Cleveland Clinic for 25 years, having served previously as Chairman of the Department of Cell Biology, and as an Associate Chief of Staff. He is currently a member of the Clinic’s Board of Governors and Board of Trustees. On a national level, he has chaired multiple NIH and American Heart Association review panels, as well as several national conferences on research into heart and vascular disease. He has published over 100 articles in his field and serves on the editorial board of multiple scientific journals. He is also director of two Cleveland Clinic spin-off companies. Adele Gulfo Adele Gulfo has spent more than 20 years at the cutting edge of healthcare, playing a pivotal role in the development of some of the world’s most successful drugs. As head of cardiovascular products for AstraZeneca and Parke-Davis, Ms. Gulfo implemented the launches for such cardiovascular drugs as LIPITOR, CRESTOR, and TOPROL-XL. In her current role as Vice President of Healthcare Innovation and Corporate Strategy for AstraZeneca, Adele oversees the Healthcare Innovation Center. The center partners with leading organizations from diverse industries to generate ideas, conduct research and implement pilot projects, enhancing the value of AstraZeneca’s medicines for the patients who need them. Before leading the Healthcare Innovation Center, Ms. Gulfo served as AstraZeneca’s Vice President of Primary Care, Cardiovascular, leading the commercialization of AstraZeneca cardiovascular products in the United States. Prior to joining AstraZeneca in 2000, she was the Senior Director, Cardiovascular Marketing, Parke-Davis, a division of Warner Lambert. Previously, Ms. Gulfo worked as a chemist and researcher for Fischer Scientific and as a market developer for a scientific technology firm. Ms. Gulfo holds a bachelor’s degree in Biology and Chemistry from Seton Hall University and a Master of Business Administration degree in Marketing from Fairleigh Dickinson University. Keith Kerman, MD Dr. Kerman joined Primus Venture Partners in 2003 and has over 12 years of private equity and operating company experience. Prior to joining Primus, Dr. Kerman was a general partner with Morgenthaler Ventures for six years and a partner with Marquette Venture Partners for two years. He has been active in both early and later stage healthcare, medical technology and life science companies. Dr. Kerman was previously an operating executive at U.S. Healthcare, where he was president of that company's subsidiary providing outsourced services to self-funded health plans. Prior to joining U.S. Healthcare, Dr. Kerman was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania, where he served on the clinical faculty at the Hospital of the University of Pennsylvania and was a Senior Fellow at the Leonard Davis Institute for Health Economics at The Wharton School. Dr. Kerman has an M.D. from Brown University and an MBA from The Wharton School of the University of Pennsylvania. Dr. Kerman focuses on the firm's medical technology, healthcare services and life sciences investment activities. Dr. Kerman is responsible for the firm's investment in excelleRx, Inc. and serves on the Board of Directors of AxioMed, Inc. and Cardio-Optics, Inc. John Rice,
PhD John is founder and Managing Partner of Triathlon Medical Ventures in Cincinnati and brings 13 years of venture investing and 13 years of research and R&D management experience in biotechnology, devices, and diagnostics. John was a Managing Director of Senmed Medical Ventures from 1989 until 2003 and served as a member of the investment committee. He also led the emerging medical technology investment efforts. He represented Senmed on the board or as board observer to several Senmed portfolio companies, including Allergenics, Athersys, Merix BioScience, Transplant Therapeutics, and Optosonics and currently represents Triathlon on the board of Kereos and is an observer to the board of Endocyte. Prior to joining Senmed Medical Ventures, John spent 13 years with Battelle Memorial Institute serving in various research, research management, and business development capacities at Battelle Memorial Institute most recently overseeing Battelle's international biotechnology activities. Locally and regionally, John was among the early organizers of Bio/Start, Cincinnati's biomedical business incubator and currently serves on its Board of Trustees. He is also a trustee of Omeris, Ohio's life science economic development organization. John also holds an adjunct appointment in the department of Molecular Virology, Immunology and Medical Genetics in the School of Medicine and Public Health at Ohio State University. He has authored numerous scientific publications and holds four patents in the fields of virology and immunology. John earned a BS degree in Microbiology, as well as MS and PhD degrees in Microbiology and Virology from The Ohio State University. Frank Samuel Frank Samuel has been involved in biomedical technology and health care issues for many years in Washington, D.C., and the State of Ohio. As a lawyer and trade association leader in Washington and a Federal and State official, he has dealt with recurring aspects of health care innovation, including public and private funding, entrepreneurship, venture capital formation, technology evaluation, and domestic and foreign government regulation. His most recent professional position was Science and Technology Advisor to the Governor of Ohio, where he was a principal architect of Ohio’s Third Frontier Project, one of the nation’s premier State initiatives to encourage economic development through support of applied research, technology commercialization and early stage capital creation. He also chaired the Governor’s Broadband Coordinating Council and Energy Coordinating Council. He currently serves on the National Advisory Council of the California Health Benefits Review Program and the Board of Directors of Providence Hospital in Washington. He has served as a member of Institute of Medicine advisory bodies on biomedical technology issues and as a member of several biomedical company boards of directors. He is a graduate of Hiram College and Harvard Law School. |
© 2007 Global Cardiovascular Innovation Center |
 |